Events - Pharvaris N.V.

Upcoming Events

Sep 15, 2026 7:45 PM EDT

Morgan Stanley 24th Annual Global Healthcare Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Sep 16, 2026 8:00 AM EDT

H.C. Wainwright 28th Annual Global Investment Conference

Click for Webcast

Add to Outlook

Add to Google Calendar

Past Events

Apr 12 - Apr 13, 2024

CIIC Spring 2024 Conference

Supporting Materials

Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 564.1 KB

Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks 756.6 KB

Mar 15 - Mar 17, 2024

2024 HAE International (HAEi) Regional Conference Americas

Supporting Materials

Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks: RAPIDe-3 Phase 3 Trial Design 2.5 MB

Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 310 KB

Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks 301.2 KB

Efficacy and Safety of Oral Deucrictibant, a Potent Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 1.1 MB

Understanding Patient Reasons not to Treat All Hereditary Angioedema (HAE) Attacks and Characteristics of Untreated HAE Attacks: Results from a Real World Survey 622.8 KB

Mar 14 - Mar 16, 2024

3rd National Congress of the Italian Network for Hereditary and Acquired Angioedema (ITACA)

Supporting Materials

Design of RAPIDe-3 Phase 3 Trial: Efficacy and Safety of the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Treatment of Hereditary Angioedema Attacks 2.5 MB

Efficacy and Safety of Bradykinin B2 Receptor Antagonism with Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 356 KB

Prophylactic Treatment with Oral Deucrictibant Improves Health-Related Quality of Life of Patients with Hereditary Angioedema 281.3 KB

Need for Caregiver Support for People Living With Hereditary Angioedema in European Countries 189.7 KB

Presentation - Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 4.8 MB

Poster - Efficacy and Safety of Oral Deucrictibant, a Bradykinin B2 Receptor Antagonist, in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 2.5 MB

Mar 6, 2024 6:00 AM EST

Extraordinary Meeting of Shareholders

Supporting Materials

Convening Notice, Agenda, and Explanatory Notes 40.8 KB

Pharvaris Announces Extraordinary Meeting of Shareholders

Proposed Articles (English) 107.2 KB

Proposed Articles (Dutch) 131.7 KB

Voting Proxy 24 KB

EGM Meeting Minutes 388.1 KB

Feb 23 - Feb 26, 2024

American Academy of Allergy, Asthma & Immunology (AAAAI) 2024 Annual Meeting

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Antagonism With Oral Deucrictibant in Prophylaxis of Hereditary Angioedema Attacks: Results of CHAPTER-1 Phase 2 Trial 250.9 KB

Riedl Audio Recording 4.5 MB

Understanding Patient Reasons Not to Treat All Hereditary Angioedema Attacks and Patient Satisfaction With On-Demand Treatment: Results From the HAE Wave II Disease Specific Programme™(DSP™) 2023 183.7 KB

Mendivil Audio Recording 4.5 MB

Feb 4 - Feb 8, 2024

Western Society of Allergy, Asthma & Immunology (WSAAI) Annual Meeting 2024

Supporting Materials

Efficacy and Safety of Bradykinin B2 Receptor Antagonism With Deucrictibant Immediate-Release Capsule for Treatment of Hereditary Angioedema Attacks: Results of RAPIDe-1 Phase 2 Trial 366.6 KB

Early-Onset Response to the Oral Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule in Patients with Hereditary Angioedema Attacks 264.3 KB

Pharvaris to Present at the WSAAI Annual Meeting 2024

Dec 7 - Dec 9, 2023

GA²LEN UCARE Conference 2023

Supporting Materials

Treatment of HAE Attacks with Deucrictibant: RAPIDe-1 Phase2 Trial Results 980.2 KB

Analyzing Symptom Relief Definitions in HAE Using AMRA and PGI-C/PGI-S 359.5 KB

Early-Onset Response to Treatment of Hereditary Angioedema Attacks with Deucrictibant 949.2 KB

Pharvaris Presents Deucrictibant Clinical Data and Analysis of Endpoints for Trials of On-demand Treatment of HAE at the GA²LEN UCARE Conference 2023

Dec 6, 2023 8:00 AM EST

CHAPTER-1 Phase 2 Top-line Data

Supporting Materials

Pharvaris Announces Positive Top-line Phase 2 Data from the CHAPTER-1 Study of Deucrictibant for the Prophylactic Treatment of HAE Attacks 177 KB

CHAPTER-1 Phase 2 Top-line Data Presentation 1.3 MB

Click for Webcast 19.5 MB

Nov 9 - Nov 13, 2023

ACAAI 2023 Annual Scientific Meeting

Supporting Materials

Deucrictibant immediate-release capsule reduces time to end of progression of hereditary angioedema attacks’ manifestations 207.4 KB

Riedl Audio Recording 7 MB

Understanding the reasons not to treat all HAE attacks and satisfaction for on-demand treatment: physician- and patient-reported data 266.5 KB

Mendivil Audio Recording 5 MB

Pharvaris Presents Deucrictibant Clinical Data and Real-World HAE Treatment Satisfaction Data at ACAAI 2023 Annual Scientific Meeting

Oct 23 - Oct 26, 2023

APAAACI 2023 International Conference

Supporting Materials

Bradykinin B2 Receptor Antagonist Deucrictibant Immediate-Release Capsule for Treatment of HAE Attacks: Phase 2 Results 1.3 MB

Pagination

First page
Previous page
…
Page 6
Page 7
Current page 8
Page 9
Page 10
Next page
Last page